Medical treatment of tinnitus.
Tinnitus is the subjective perception of sound that does not exist. Tinnitus is caused by an altered discharge in the auditory pathway from hair cell to cortex and back. Intravenous Xylocaine acts by blocking 10% of the transmission through each synapse, having more effect on the slow multisynaptic pathway through the reticular formation than the rapid pathway to have more effect on the low frequency slow pathway tinnitus than the rapid pathway high frequency tinnitus. Tocainide, the oral amide of Xylocaine, is of great value in the treatment of tinnitus responsive to intravenous Xylocaine.
D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014012:Tinnitus / Q000188:drug therapy* / Q000503:physiopathology; D016677:Tocainide
D016677:Tocainide; D008012:Lidocaine